Injury & recovery

BPC-157 Fragment

Gray market

Checked 18 Oct 2026 · 23 sources · 10 corrections on this page · No vendors · No affiliates · No one buys a word of it

0 published studies

No Data · Every mechanism claim is borrowed from the full BPC-157

Gray market · No FDA ruling — not on any list

Sold as a research chemical. Some clinics and pharmacies still supply it; that’s their risk, not a change in the rule.

Bottom line

The parent has animal studies and three human pilots; the fragment has none.

Also called: Shorter active-core variants of BPC-157
GEPPP / GEPPPGK / GEPPPGKP
"BPC-157 short"
occasionally "BPC-15"
Category: Peptide — Tissue Repair (Derivative of BPC-157)
Parent Peptide: BPC-157 (GEPPPGKPADDAGLV, 15 aa)
Fragment Length: 5–8 amino acids
Molecular Weight: ~470–700 Da (sequence-dependent)
Half-life: Not measured
Route (studied): No study of it
Route (sold): SubQ vials (research chemical)
FDA Status: Research-only
Fragment-Specific Studies: Essentially none
WADA Status: Not specifically named — prohibited at all times under S0 (no government has approved it for human use)
Cost & Access: Research-only

Also for injury & recovery

The other four questions

What does it do? Claimed to keep the tissue-repair activity of the full peptide by keeping a key segment. Nothing has been demonstrated. Every mechanism claim is borrowed from the full BPC-157.
Who uses it? A small niche of self-experimenters buying it for a modest price discount over the full peptide. Research-chemical channels only.
Does the evidence hold up? Zero peer-reviewed studies on the fragment itself. Zero human trials. The lab that dominates BPC-157 research has never published a minimum-active-core breakdown. A 2025 commentary raised the question and nobody answered.
Bottom line? The parent has animal studies and three human pilots; the fragment has none.

Dosing from the Literature

Published for tendon and gut repair: nothing on the fragment; the doses below are borrowed from BPC-157. Not published: any fragment dose, in animals or people.

No study has given any BPC-157 fragment to an animal or a person. The rows below record what community sources describe, with no study behind any of them.

Route	Dose Range	Frequency	Notes
Any route	No dose published	—	No fragment-specific dose-response study exists, in any species.

Dosing Disclaimer

BPC-157 Fragment has never been dose-finding-studied in any species, in the peer-reviewed literature. Community doses are extrapolated from parent BPC-157 protocols and are pure inference. Optimal dose for the fragment is unknown and may differ substantially from the parent peptide. Which dose fits a given person is a question for a licensed healthcare provider.

→ Calculator — vial-to-syringe math

What It Is

BPC-157 Fragment refers, in current optimization-community usage, to one of several shorter sequences derived from the full BPC-157 pentadecapeptide (GEPPPGKPADDAGLV, 15 amino acids). The most commonly synthesized and sold "fragment" forms are the N-terminal pentapeptide (a chain of 5 amino acids) GEPPP (5 amino acids), the heptapeptide (a chain of 7 amino acids) GEPPPGK (7 amino acids), and occasionally the octapeptide (a chain of 8 amino acids) GEPPPGKP (8 amino acids). Some vendors also sell a "C-terminal fragment (a piece from the tail end of the peptide chain)" (the second half of the parent sequence, GKPADDAGLV or shorter slices) but this is much less common and even more poorly characterized.

The conceptual rationale for a "fragment" form mirrors what happened with TB-500 / Thymosin Beta-4: independent investigators showed that a short 7-amino-acid stretch within the full 43-amino-acid parent (the LKKTETQ "actin-binding" region, often referred to as TB-500 Fragment 17-23) appeared to retain a meaningful subset of the parent peptide's biological activity at a fraction of the synthesis cost. Vendors and informed users have asked the analogous question about BPC-157: is there a shorter "active core" that retains the parent's tissue-repair signaling at a lower synthesis cost? The honest answer in 2026 is that nobody has published a definitive demonstration of which subset (if any) of BPC-157 carries the bulk of its activity. The Sikiric group — who control essentially all of the parent BPC-157 literature — has consistently used the full 15-amino-acid sequence in their published work and has not published systematic structure-activity-relationship dissection to identify a minimal active core.

A 2025 commentary in Inflammopharmacology by an outside reader of Sikiric's work explicitly raised the question of "modified pentapeptide" bioactivity in the BPC-157 context — noting the unusual triple-proline motif (GE-PPP-GK) at the N-terminus and asking whether this motif alone might carry meaningful organ-protective activity. That question has not been answered in the peer-reviewed literature. Compounds sold as "BPC-157 fragment" through research-chemical channels are therefore being purchased on a hypothesis, not on data.

Practically, this means the BPC-157 Fragment category is one rung lower in evidence-quality than parent BPC-157 itself — and parent BPC-157 already has only three small published human pilot studies (all from a single research group). The fragment is a derivative compound whose biological equivalence to the parent has not been demonstrated, whose minimal-active-sequence question is unresolved, and whose vendor identity (which specific shorter sequence is in the vial) varies.

Mechanism of Action

The mechanism here is necessarily speculative and inferential — by analogy to parent BPC-157's pleiotropic (having many effects at once) mechanism rather than from fragment-specific data. The proposal is that the N-terminal triple-proline-containing region (GEPPP) carries the structural feature responsible for at least some of the parent peptide's activity.

The structural rationale (triple proline) — BPC-157 contains an unusual GE-PPP-GK motif at its N-terminus. Triple-proline sequences impart conformational rigidity (proline-induced kinks) and resistance to proteolytic cleavage. The 2025 Inflammopharmacology commentary asked whether this motif alone is sufficient for stability and bioactivity. The hypothesis is reasonable; the data is absent.
By-analogy mechanism (parent BPC-157) — If a fragment retains parent activity, the proposed downstream pathways are the same as for parent BPC-157: VEGFR2-Akt-eNOS angiogenic signaling, Src-Caveolin-1-eNOS independent NO production, FAK-paxillin cell migration, growth hormone receptor upregulation in fibroblasts, bidirectional NO system modulation, ERK1/2 signaling, dopaminergic (related to dopamine signaling)/serotonergic (related to serotonin signaling) neurotransmitter modulation, and gastric mucosal cytoprotection. None of these have been demonstrated for the fragment specifically.
Why fragments often lose activity — In peptide pharmacology, shorter fragments typically retain a subset of parent activity at most. Receptor binding generally requires multiple residues across the parent sequence to engage cleanly; truncating loses binding interactions. The thymosin β4 fragment 17–23 case is unusual: its actin-binding stretch, LKKTETQ (TB-500 is an acetylated copy), matched the whole protein in endothelial-cell and chick aortic-arch tests (Philp, Huff et al., 2003) and in wound repair in aged mice (Philp, Badamchian et al., 2003); no published study has given TB-500 to people (FDA TB-500 review, 2026). It is not the typical outcome.
Why fragments sometimes outperform parent — Occasionally a shorter fragment is more BBB-permeable, has a different metabolic profile, or evades a regulatory binding partner that constrains the parent. The BPC-157 N-terminal pentapeptide could theoretically have improved oral or transdermal absorption simply by virtue of its smaller size and different lipophilicity profile. Speculative.
Vendor identity ambiguity — Different vendors selling "BPC-157 fragment" mean different things. Some sell GEPPP (5 aa), some sell GEPPPGK (7 aa), some sell C-terminal slices (KPADDAGLV or shorter), and a minority sell mislabeled product entirely. Mass-spectrometry confirmation is the only way to know what is actually in the vial.
What is mechanistically certain — Nothing is mechanistically certain about the fragment beyond "it is a shorter sequence of BPC-157 amino acids." Any specific mechanistic claim rests on analogy to parent BPC-157, not on established fragment-specific evidence.

What the Research Shows

Direct fragment research is essentially non-existent in the peer-reviewed literature. The Sikiric group has worked with related shorter peptides under codes including PL-10 in the broader BPC family but has not published a systematic structure-activity-relationship dissection of BPC-157 with isolated activity-mapping for the GEPPP motif or other shorter slices.

Parent BPC-157 evidence base (provides only inferential support) — The 2025 Vasireddi systematic review (HSS J; PMID 40756949) screened 544 BPC-157 articles and included 36; essentially none of these address fragment-specific activity. The McGuire 2025 narrative review and the Józwiak 2025 literature-and-patent review similarly focus on the parent pentadecapeptide.
Older BPC-family work (PL-10, PL-14736) — Sikiric's group has published on related BPC-family designations including PL-10 and PL-14736. PL-14736 is broadly equivalent to BPC-157 (the names refer to the same 15-amino-acid sequence in different commercial / regulatory contexts). Earlier shorter sequences (PL-10) were largely abandoned in favor of the 15-aa pentadecapeptide because it offered the best balance of stability and activity in the original ulcer models.
2025 Inflammopharmacology commentary — A 2025 reader-response commentary on Sikiric's 2024 review (PMC12396989) raised the explicit question of pentapeptide bioactivity, noting the structural significance of the GE-PPP-GK motif. This is a research question, not an answer.
No human trial of any BPC-157 fragment — A search of ClinicalTrials.gov returns no registered human trial of any BPC-157 fragment as of April 2026.
No independent peer-reviewed preclinical study — A targeted PubMed search for "BPC-157 fragment," "GEPPP peptide," and similar terms returns no peer-reviewed studies that isolate fragment activity in a tendon, gut, vascular, or wound-healing model.
Vendor / community claims do not constitute evidence — Some vendors selling BPC-157 fragment products cite parent BPC-157 evidence as if it applies to the fragment. It does not. A shorter sequence is a different chemical entity with potentially different binding, distribution, metabolism, and excretion. Parent evidence cannot be transferred to a fragment without a fragment-specific study.

Critical Context — Evidence Gap

Among compounds in this database, BPC-157 Fragment has one of the largest evidence-to-marketing gaps. There is essentially no fragment-specific peer-reviewed evidence — yet the product is sold on the strength of parent BPC-157's preclinical literature, which itself is heavily concentrated in a single research group. Anyone using the fragment is working from a hypothesis ("the active core of BPC-157 is in the N-terminal segment") that has not been demonstrated. The fragment is a research-only experimental compound, not a leaner version of an established peptide.

Human Data

There is no published human study of any BPC-157 fragment. The published human evidence for parent BPC-157 itself is limited to three small pilot studies (all from a single research group) and a Phase I safety registration with no posted results (NCT02637284) — none of which apply to fragment forms.

No fragment-specific human trial registered — A search of ClinicalTrials.gov for "BPC-157 fragment," "GEPPP," and related terms returns no registered trials as of April 2026.
No published case series, observational study, or pilot — Unlike parent BPC-157 (3 published Lee-group pilots), there is no published clinical experience with the fragment.
Anecdotal community reports only — Forum posts, podcast interviews, and practitioner reports occasionally describe BPC-157 fragment use. These are uncontrolled, selection-biased, and cannot substitute for clinical evidence.
Parent BPC-157 human evidence (for context only) — Lee & Burgess 2025 IV pilot (n=2); Lee, Walker & Ayadi 2024 interstitial cystitis pilot (n=12); Lee & Padgett 2021 knee pain retrospective (n=16). These are the parent peptide; they do not apply to the fragment.
Practical implication — Anyone using BPC-157 fragment is adopting a compound with zero published human safety, efficacy, dose-response, or pharmacokinetic data of any kind.

Reconstitution & Storage

No label or guideline gives a strength, storage condition or shelf life for a BPC-157 fragment. The table is arithmetic only: what a vial of a given size holds once dissolved (U-100 insulin syringe: 100 units = 1 mL). It is not a recommendation.

Vial Size	BAC Water	Concentration
5 mg	2 mL	2,500 mcg/mL
10 mg	2 mL	5,000 mcg/mL

Side Effects & Risks

Important

No study has given any BPC-157 fragment to an animal or a person, so nothing is known about its safety (PubMed and ClinicalTrials.gov). The parent's toxicology does not transfer. Consult a licensed healthcare provider.

The fragment-specific side-effect profile is essentially unknown. Community reports overlap with parent BPC-157 reports — but with even less data underpinning them.

Theoretical pro-angiogenic / tumor concern — If the fragment retains any subset of parent BPC-157's VEGFR2 upregulation activity, the same theoretical concern about promoting growth in existing tumors or precancerous lesions applies. Whether the fragment retains this activity is unknown. Cancer screening before initiation is reasonable risk-management.
WADA status — BPC-157 was banned by WADA in 2022 under category S0 (non-approved substances). A fragment of it is not named on the 2026 Prohibited List, but S0 prohibits any substance no government has approved for human therapeutic use (WADA Prohibited List 2026). USADA has issued explicit advisories against any BPC-157-related substance.
No identified lethal dose — No formal toxicology study exists. The parent BPC-157 toxicology (Xu et al. 2020 — no LD1 in mice, rats, rabbits, dogs) provides only inferential reassurance.
The biggest unknown — Whether the fragment has any biological activity at all. A non-active product carries the safety profile of the inactive vehicle plus whatever contaminants are present, but offers none of the parent's claimed benefits.

Bloodwork & Monitoring

No trial, label or guideline sets monitoring for a BPC-157 fragment, and no study of one has been published (PubMed and ClinicalTrials.gov).

Commonly Stacked With

No published study has combined a BPC-157 fragment with anything.

Stacking this? Read the receipt →

Legal Status

Current Status — April 2026

BPC-157 Fragment is not FDA-approved for any indication. It is a research-only compound, and shorter than its parent BPC-157 — which was removed from FDA Category 2 on April 22, 2026 (FDA notice April 15, 2026), was recommended by PCAC on July 23–24, 2026, and is still not legal to compound while rulemaking is pending. BPC-157 Fragment is not on any FDA 503A bulk-substance list.

In late February 2026 the HHS secretary said on a podcast that he expected FDA to change the status of “about 14” peptides within “a couple of weeks” (NPR, March 31, 2026); those were public remarks, reported, not a rule. FDA’s documented step came on April 15, 2026: notice that 12 peptides would leave Category 2 because their nominations had been withdrawn, removed on April 22, which left them in no category rather than Category 1 (FDA 503A categories list, April 22, 2026). Parent BPC-157 was among the 12; BPC-157 fragments were not. Even if the parent BPC-157 is reclassified, BPC-157 fragments are different chemical entities and would not automatically inherit that status. Each shorter sequence would need its own bulk-substance evaluation.

BPC-157 was banned by WADA in 2022 under category S0 (non-approved substances). Detection methods (UHPLC-HRMS) for parent BPC-157 are now established; whether these methods would also detect the fragment depends on the specific fragment sequence and the testing laboratory's methodology.

Cost & Access

BPC-157 Fragment is not approved for human use. It is available through research suppliers for laboratory research purposes only.

Parent BPC-157 cannot currently be legally compounded by U.S. 503A or 503B pharmacies under existing FDA bulk-substance rules. Shorter fragment sequences are even more clearly outside any approved-compounding pathway. Online research-chemical channels list BPC-157 fragment products at variable prices, modestly lower than parent BPC-157 due to the shorter (cheaper-to-synthesize) sequence. The cost saving versus the parent is real but modest, and is largely offset by the absence of fragment-specific evidence and the elevated identity-verification burden.

FDA’s April 2026 notice names BPC-157 at the parent-sequence level; no BPC-157 fragment appears on FDA’s 503A categories list (FDA 503A categories list, May 14, 2026). Each fragment sequence would, in principle, require its own evaluation by the Pharmacy Compounding Advisory Committee (PCAC) before becoming compoundable. Practically, the fragment is unlikely to receive distinct regulatory attention unless a sponsor advances it — and no sponsor is publicly doing so as of April 2026.

Pricing and availability vary by vendor, country, and prescription status. Kalios does not sell compounds.

Next Steps

→ Compare with the parent BPC-157 →

→ Calculator — vial-to-syringe math →

→ Every Injury & recovery compound →

References

Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993. PMID: 8298609. (Foundational parent BPC-157 paper.)
Sikiric P, Seiwerth S, Grabarevic Z, Petek M, Rucman R, Turkovic B, et al. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. (Clarifies BPC-157 nomenclature as the 15-aa pentadecapeptide selected from the larger parent BPC protein.)
Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949. (Parent BPC-157 systematic review — does not address fragment-specific evidence; included as the most current parent-peptide evidence summary.)
McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID: 40789979. (Parent peptide; raises evidence-quality concerns applicable to fragment by extension.)
Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID: 40005999. (Parent peptide; reviews structural features including the GE-PPP-GK motif relevant to fragment hypothesis.)
Whitehouse M. Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant... Inflammopharmacology. 2025. (PMC12396989.) (Reader-response commentary on Sikiric 2024; explicitly raises the question of pentapeptide-fragment bioactivity.)
Sikiric P, Sever M, Krezic I et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract, significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organ protection. Inflammopharmacology. 2024. DOI: 10.1007/s10787-024-01499-8. (Most recent comprehensive Sikiric-group review of parent BPC-157.)
Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Vrcic H, Sebecic B. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. PMID: 21548867. (Parent peptide reference for mechanism — applies to fragment only by inference.)
Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID: 27847966. (Independent VEGFR2 mechanism paper for parent peptide.)
Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078. PMID: 33051481. (Independent Src-Cav-1-eNOS mechanism paper for parent peptide.)
Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. PMID: 40131143. (Parent peptide human pilot — does not apply to fragment.)
Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. PMID: 39325560.
Lee E, Padgett B. Intra-articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435.
Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. PMID: 32334036. (Parent BPC-157 toxicology — no LD1 in mice/rats/rabbits/dogs.)
USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. U.S. Anti-Doping Agency. usada.org. (Applies to parent and by extension to fragment.)
ClinicalTrials.gov. PCO-02 - Safety and Pharmacokinetics Trial (PharmaCotherapia). NCT02637284. (Parent peptide; no fragment-specific trial registered.)
FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025–2026. (BPC-157 fragment shorter sequences are not specifically listed; parent BPC-157 was removed from Category 2 on April 22, 2026.)
WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org. (BPC-157 family banned under S0; fragment plausibly included by analogy.)
FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
Stone W. The wellness world is eager for RFK Jr.’s promised move on peptides. NPR, March 31, 2026. npr.org/2026/03/31/nx-s1-5768206/peptides-rfk-fda-compounding-pharmacies. Read October 3, 2026. (The HHS secretary’s late-February podcast remarks, “about 14” peptides; reported, not a rule.)
Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105. PMID: 14500546. DOI: 10.1096/fj.03-0121fje.
Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. PMID: 12581423. DOI: 10.1046/j.1524-475x.2003.11105.x.
FDA. FDA Evaluation of TB-500-Related Bulk Drug Substances (TB-500 (Free Base) and TB-500 acetate). Pharmacy Compounding Advisory Committee briefing document for the meeting of July 23–24, 2026 (memorandum dated May 15, 2026). fda.gov/media/193349/download. Read October 4, 2026.